Ani Pharmaceuticals INC Form 4 insider transactions

ANI Pharmaceuticals SVP Ori Gutwerg received a restricted stock award of 12,969 shares and had 2,221 shares withheld for tax purposes.

ANI Pharmaceuticals SVP Chad Gassert acquired 11,116 shares of common stock through a restricted stock award, increasing his direct beneficial ownership.

Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals, acquired 10,810 shares of common stock through a restricted stock award and disposed of 1,555 shares for tax purposes.

ANI Pharmaceuticals' Senior VP, General Counsel & Secretary, Meredith Cook, reported the acquisition of 13,895 restricted stock units and the sale of 1,555 shares for tax purposes.

ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, reported the acquisition of 22,233 restricted shares and the disposition of 2,773 shares for tax purposes.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, sold 5,323 shares of common stock for approximately $415,290 under a pre-arranged trading plan.

Krista Davis, SVP and Chief HR Officer at ANI Pharmaceuticals, sold 3,814 shares of common stock in February 2026 as part of a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, disposed of 5,503 shares of common stock for tax purposes related to performance stock unit vesting.

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals, disposed of 3,011 shares of common stock for tax withholding related to vested performance units.

ANI Pharmaceuticals' SVP, Chief HR Officer Krista Davis, disposed of 3,017 common shares for tax purposes following the vesting of performance stock units.

ANI Pharmaceuticals' SVP of Corporate Development and Strategy, Chad Gassert, reported a tax-related disposition of 4,269 common shares following the vesting of performance stock units.

ANI Pharmaceuticals' SVP of Generics, Ori Gutwerg, disposed of 4,267 shares of common stock at $76.25 per share to cover tax obligations related to PSU vesting.

ANI Pharmaceuticals' Head of Rare Disease, Christopher Mutz, disposed of 4,546 shares of common stock for tax withholding related to PSU vesting.

ANI Pharmaceuticals' SVP, Thomas Rowland, reported the withholding of 1,762 shares for tax purposes related to the vesting of performance stock units.

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc., sold 500 shares of common stock for $84.33 per share as part of a pre-arranged trading plan.

Krista Davis, SVP and Chief HR Officer at ANI Pharmaceuticals, sold 1,622 shares of common stock for $82.40 per share under a pre-arranged trading plan.

ANI Pharmaceuticals' SR. VP, General Counsel & Secretary, Meredith Cook, sold 400 shares of common stock for $82.32 per share under a Rule 10b5-1 trading plan.

ANI Pharmaceuticals Director Renee P. Tannenbaum sold 1,800 shares of common stock for $81.15 per share, reducing her direct beneficial ownership to 25,157 shares.

ANI Pharmaceuticals Director Patrick D. Walsh reported the sale of 8,643 common shares and a gift of 3,000 shares to a charitable fund on November 13, 2025.

Chad Gassert, SVP of Corporate Development and Strategy at ANI Pharmaceuticals Inc., sold common stock totaling 14,736 shares in two transactions in November 2025.

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals, plans to sell 400 shares of common stock for $87.27 per share under a pre-arranged trading plan.

ANI Pharmaceuticals' SR. VP, General Counsel & Secretary, Meredith Cook, reported a planned sale of 400 shares of common stock for $90.09 per share scheduled for October 13, 2025.

Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals, sold 1,000 shares of common stock for $98.04 per share pursuant to a Rule 10b5-1 trading plan.

Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, disposed of 1,710 shares of common stock for tax purposes related to restricted stock vesting.

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc., sold 400 shares of common stock at $98.42 per share under a pre-arranged trading plan.

ANI Pharmaceuticals Director Antonio R. Pera reported the sale of 7,292 shares of common stock for $94.94 per share, effective September 3, 2025, under a pre-arranged 10b5-1 plan.

ANI Pharmaceuticals Director Matthew J. Leonard sold 2,528 shares of common stock for $90.62 per share as part of a pre-arranged trading plan.

Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals Inc., reported the sale of 1,763 shares of common stock at a weighted average price of $91.1 per share under a Rule 10b5-1 plan.

ANI Pharmaceuticals' Head of R&D and COO-Novitium Ops, Muthusamy Shanmugam, sold 100,000 shares of common stock for over $9 million in August 2025.

ANI Pharmaceuticals Director Jeanne Thoma sold a total of 21,540 shares of common stock for approximately $1.92 million under a Rule 10b5-1 plan.